Navidea Biopharma (NAVB) Tops Q3 EPS by 2c; Revenue Beats

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.47 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Ennis (EBF) Reports In-Line Q1 EPS
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance